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Abstract
Introduction: Lung cancer is a major cause of mortality and morbidity worldwide. Galectin-3 is multifunctional
protein, which is involved in regulation of cell growth, cell adhesion, cell proliferation, angiogenesis and apoptosis.
Cyclin D1 together with other cyclin plays an important role in cell cycle control. Cyclin D1 regulates the G1-to-S
phase transition. The aim of this study was the evaluation of correlations between clinicopathological findings and
cyclin D1 and galectin-3 expression in non-small cell lung cancer (NSCLC). We wanted also to analyze the
prognostic value of cyclin D1 and galectin-3 expression. Moreover we tried to evaluate the correlations between
galectin-3 and cyclin D1 expression in tumor tissue.
Materials and methods: We used the immunochemistry method to investigate the expression of galectin-3 and
cyclin D1 in the paraffin-embedded tumor tissue of 47 patients (32 men and 15 women; mean age 59.34 ± 8.90).
years. We used monoclonal antibodies to cyclin D1 (NCL-L-cyclin D1-GM clone P2D11F11 NOVO CASTRA) and to
galectin-3 (mouse monoclonal antibody NCL-GAL3 NOVO CASTRA).
Results: Galectin-3 expression was positive in 18 cases (38.29%) and cyclin D1 in 39 (82.97%). We showed only
weak trend, that galectin-3 expression was lower in patients without lymph node involvement (p = 0.07) and
cyclin D1 expression was higher in this group (p = 0.080). We didn’t reveal differences in cyclin D1 and galectin-3
expression in SCC and adenocarcinoma patients. We didn’t demonstrated also differences in galectin-3 and cyclin
D1 expression depending on disease stage. Moreover we analyzed the prognostic value of cyclin D1 expression
and galectin-3 in all examinated patients and separately in SCC and in adenocarcinoma and in all stages, but we
didn’t find any statistical differences. We demonstrated that in galectin-3 positive tumors cyclin D1 expression was
higher (96.55% vs 61.11%, Chi
2 Yatesa 7.53, p = 0.0061) and we revealed negative correlation between cyclin D1
and galectin-3 expression (R Spearman -0.458, p = 0.0011). In squamous cell lung cancer we didn’t observed
correlations between these both examinated markers (R = -0.158, p = 0.460), and in adenocarcinoma the negative
correlation was very strong (R = -0.829 p = 0.000132).
Conclusions: We didn’t reveal any important correlations between clinicopathological findings and galectin-3 and
cyclin D1 expression and in non small cell lung cancer. We didn’t observed also prognostic value of cyclin D1 or
galectin-3 expression. But we showed higher cyclin D1 expression in galectin-3 negative tumor tissues. We
revealed also differences in correlations between galectin-3 and cyclin D1 expression in two main histopathological
types of NSCLC.
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Lung cancer is the most commonly diagnosed cancer as
well as the death cause in males. Among females it is the
fourth cancer worldwide and the second leading cause of
cancer death. Although in developed countries consists
the second common neoplasm in females [1,2]. The over-
all 5-year survival rates of lung cancer patients remain
relatively poor. EUROCARE-4 the large population study
on survival of adult Europeans with cancer, reported that
mean age-adjusted 5-year survival for lung cancer was
12.5%. This survival rate seems to be very low especially in
comparison with survival in another carcinomas (colorec-
tal-53.8%, breast-78.9%, prostate-75.7%, ovarian-36.3%)
[3]. Currently the most powerful prognostic tool in lung
cancer is the stage of disease. Differing survival outcomes
among patients within a stage suggests the existence of
other tumor factors affecting prognosis. Such factors could
potentially be used to further classify patients into groups
according to sub-stages that may be treated differently.
Galectin-3 belongs to the evolutionary conserved family
of 15 carbohydrate-binding proteins that are widely dis-
tributed in normal and neoplasmatic cells [4]. Galectin-3
is a 31 kDa molecule, that consists of three domains: a
NH2 terminal domain, a repetitive collagen-like sequence
rich in glycine, proline and a COOH-terminal carbohy-
drate recognition domain (CRD, lectin domain)[5]. CRD is
responsible for the specificity of galectins for saccharides
[6]. This intracellular and extracellular lectin is able to
interact with many molecules including glycoproteins, cell
surface molecules and extracellular matrix proteins [5].
Galectin-3 is multifunctional protein, which is involved in
regulation of cell growth, cell adhesion, cell proliferation,
angiogenesis and apoptosis. Intracellular galectin-3 could
inhibit cell apoptosis induced by chemotherapy agents
such as cisplatin and etoposide [7]. The connection with
cancer progression and oncological drug resistance indi-
cate that galectin-3 seems to be promising target for the
development of novel oncological therapeutic strategies
[6,7]. Uncontrolled cell proliferation is the hallmark of
malignant tumors that is why the evaluation of the prog-
nostic significance of the expression of proteins involved
in regulation of cell proliferation remains promising.
Cellular proliferation is regulated by protein complexes
composed of cyclins and cyclin-dependent kinases (cdks).
Five major families of cyclins (termed A, B, C, D, and E)
have been isolated and characterized. Cyclin D1 reaches it
peak of synthesis and activity during the G1 phase, and is
believed to regulate the G1-to-S phase transition [8,9].
Cyclin D1 plays a role in DNA repair. Cyclin D1 could
bind directly RAD51, a recombinase that drives the homo-
logous recombination process [10]. Cyclin D1 gene is
located in the chromosome 11q13 [11]. The expression of
cyclin D1 and other cyclins has been often evaluated in
many cancers and its prognostic value is disputable.
In esophageal squamous cell carcinoma and hepatocellular
carcinoma the expression of CyclinD1 has been reported
to be associated with poor outcomes [12-14].
The aim of this study was the evaluation of correlations
between clinicopathological findings and cyclin D1 and
galectin-3 expression in non-small cell lung cancer. We
wanted also to analyze the prognostic value of cyclin D1
and galectin-3 expression. Moreover we tried to evaluate
the correlations between galectin-3 and cyclin D1 expres-
sion in tumor tissue.
Materials and methods
The 47 patients with non-small cell lung cancer (32 men
and 15 women) were evaluated. The mean age of the
patients was 59.34 ± 8.90 years. All patients had under-
gone the surgical treatment (lobectomy, bilobectomy,
pneumonectomy or diagnostic thoracotomy). The histo-
pathologic diagnosis was squamous cell carcinoma in 24
patients, adenocarcinoma in 15 patients, large cell carci-
noma in 4 patients and non- small cell lung cancer of
unspecified type in 4 patients. Based on the TNM staging
system: 17 patients were in stage I (including IA-5 per-
sons, IB-12), 8 in II (IIA- 1, IIB-7), 16 in III (IIIA-13, IIIB-
3) and in 6 IV.
Twenty-one patients received chemotherapy-treatment,
in this group 12 persons neoadjuwant chemotherapy.
In all patients the 24 month survival has been evaluated.
Twenty seven (57.45%) patients were alive and 20
(42.55%) died. The average survival time was 18.91 ± 7.14
months.
The work has been approved by the appropriate ethi-
cal committees related to the institution.
Immunohistochemistry
Formalin -fixed well preserved tumor tissue blocks from
surgically resected lung cancer specimens were used for
immunohistochemical study. The 4 μm-sections of forma-
lin -fixed tissues were mounted on silanized slides, depar-
affinized in xylene and rehydrated through serial baths of
alcohol to water. The hydrated sections were treated in 3%
hydrogen peroxide for 10 minutes to eliminate endogen-
ous peroxidase activity and washed in phosphate-buffered
saline (PBS).
The primary antibodies used in this study were:
Galectin-3 mouse monoclonal antibody NCL-GAL3
NOVO CASTRA and Cyclin D1 monoclonal antibody
(NCL-L-CYCLIN D1-GM clone P2D11F11 NOVO
CASTRA).
The monoclonal antibody-treated slides were raised in
PBS solution and incubated with a biotinylated secondary
antibody (LSAB
R+ Kit DAKO). The slides were washed in
PBS and then incubated with an avidin-biotin-peroxidase
complex (LSAB
R+ Kit, DAKO K 0675) for 15 minutes.
After washing with PBS, a chromogenic reaction was
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hydrochloride (DAB+, Liquid K 3486 DAKO).
Positive staining appeared as brown cell plasma or
nucleus. The galectin-3 and cyclin D1 expression was
described as positive if more than 10% of cells were
stained.
Statistical method
Statistical analysis was performed using the CSS Statis-
tica for Windows (version 5.0). Chi-square test was used
among two or multiple groups. Differences between
samples were considered significant at p < 0.05. Survival
curves were constructed using Kaplan-Meier method.
Results
The galectin-3 expression was revealed in 18 cases
(38.29%). Only cytoplasmatic staining war observed.
Figure 1 shows pictures of immunohistochemical stain-
ing (Figure 1).
In squamous cell carcinoma (SCC) galectin-3 expression
was positive in 11 from 24 tumor specimens (45.83%), in
adenocarcinoma in 4 from 15 (26,67%), in large cell carci-
noma in 2 from 4 (50%) and in non- small cell lung cancer
of unspecified type in 1 from 4 (25%). We compared galec-
tin-3 expression in two main histopathogical types: SCC
and adenocarcinoma, but any statistical significant differ-
ences were revealed (Chi
2 Yatesa 0.74, p = 0.390). We
didn’t perform comparison in another histopathological
types because of the small numerous of the groups.
In stage I galectin-3 was positive in 3 from 17 tumor
specimen (17.65%), in stage II in 5 from 8 (62.5%), in stage
III 7 from 16 (43.75%) and in stage IV in 3 from 6 (50%).
We didn’t reveal differences in galectin-3 expression
depending on disease stage. We wanted also to analyze if
chemotherapy before surgical treatment (neoadjuwant
therapy) could change galectin-3 expression in tumour tis-
sue, that is why we performed comparison of galectin-3
expression in patients, who received neoadjuwant che-
motherapy and patients, who didn’t receive chemotherapy
before surgery. In the first group galectin-3 expression was
positive in 5 tumour tissues from 12 (41.6%) and in the
second group in 13 from 35 (37.14%). The difference was
not significant. Moreover we compared galectin-3 expres-
sion in patients with lymph nodes metastases (N1 and N2)
and in patients without (N0). In patients with lymph node
metastases galectin-3 expression was revealed in 13 from
25 cases (52%), and without lymph node metastasis in 5
from 22 (22.7%). In Chi
2 test the difference was significant
(p = 0.039), but in Chi
2 Yatesa test there was only ten-
dency (p = 0.07).
We analyzed the prognostic value of galectin-3 expres-
sion in all patients with NSCLC and separately in
patients with SCC and adenocarcinoma, and separately
in every stage, but we didn’tf i n da n ys t a t i s t i c a ls i g n i f i -
cant differences (Table 1 and Figure 2).
T h i r t y - n i n eo f4 7( 8 2 . 9 7 % )t u m o rt i s s u es p e c i m e n s
were positive for cyclin D1. Only cytoplasmatic staining
were observed (Figure 1). We analyzed cyclin D1 expres-
sion in two main histopathological types. In SCC positive
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Figure 1 Immunohistochemical staining.A .n e g a t i v e
immunostaining; B.positive cytoplasmatic cyclin D1 immunostaining;
C.positive cytoplasmatic galectin-3 immunostaining.
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(87.5%) and in adenocarcinoma in 12 from 15 (80%).
There was no significant differences in cyclin D1 expres-
sion (Chi
2 Yatesa 0.03; p = 0.860). We didn’t reveal also
differences in cyclin D1 expression in male and female
(p = 0.964). In stage I cyclin D1 was positive in all 17
tumor specimen (100%), in stage II in 4 from 8 (50%), in
stage III 14 from 16 (87.5%) and in stage IV in 4 from 6
(66.7%). We didn’t reveal differences in cyclin D1 expres-
sion depending on disease stage. The cyclin D1 was
Table 1 The comparison of 24 months survival and galectin-3 expression in selected groups of patients.
Survival Positive
galectin-3
expression n (%)
Negative galectin-3 expression n (%) Chi
2
Yatesa
p Cox Mantel
All examinated patients with NSCLC
< 24 months 8 (44.44%) 12 (41.38%) 0.01 0.922 0.841
≥ 24 months 10 (55.56%) 17 (58.62%)
The patients with squamous cell carcinoma
< 24 months 5 (45.45%) 5 (38.46%) 0.00 0.944 0.612
≥ 24 months 6 (54.55%) 8 (61.54%)
The patients with adenocarcinoma
< 24 months 2 (50%) 6 (54.55%) 0.18 0.667 0.695
≥ 24 months 2 (50%) 5 (45.45%)
Stage I
< 24 months 1 (33.33%) 2 (14.29%) 0.00 0.960 0.434
≥ 24 months 2 (66.66%) 12 (85.71%)
Stage II
< 24 months 2 (40%) 3 (100%) 0.89 0.345 0252
≥ 24 months 3 (60%) 0 (0%)
Stage III
< 24 months 2 (28.57%) 5 (55.56%) 0.33 0.567 0.275
≥ 24 months 5 (71.43%) 4 (44.44%)
Stage IV
< 24 months 3 (100%) 2 (66.67%) 0.00 1.00 0.341
≥ 24 months 0 (0%) 1 (33.33%)
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Figure 2 Cumulative proportion of survival Kaplan- Meier in all patients with non-small cell lung cancer according to: A galectin-3
expression; B. cyclin D1 expression.
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(N1 or N2) and in patients without lymph node involve-
ment (N0). In patients with N0 cyclin D1 was positive in
21 from 22 cases and in patients with N1 or N2 cyclin
was positive in 18 from 25. In Chi
2 test the difference
was significant (Chi
2 4.46; p = 0.032), but in Chi
2 Yatesa
test there was only tendency (3.05, p = 0.080)
We analyzed the prognostic value of cyclin D1 expres-
sion in all patients with NSCLC and separately in
patients with SCC and adenocarcinoma, and separately
in every stage, but we didn’tf i n da n ys t a t i s t i c a ls i g n i f i -
cant differences (Table 2 and Figure 2).
We decided also to compare correlations between
cyclin D1 and galectin-3 expression. In galectin-3 positive
tumors cyclin D1 was positive in 11 from 18 (61.11%)
and in galectin-3 negative was positive in 28 from 29
(96.55%). The difference was statistical significant (Chi
2
Yatesa 7.53, p = 0.0061) and the Spearman’s correlation
coefficient confirmed negative correlation between cyclin
D1 and galectin-3 expression (R Spearman -0.458, p =
0.0011). We tried also to compare correlations between
examinated markers in both main histopathological
types. In squamous cell lung cancer we didn’t observed
correlations between these both examinated markers (R =
-0.158, p = 0.460), and in adenocarcinoma the negative
correlation was very strong (R = -0.829 p = 0.000132).
Discussion
Many studies indicate on enorm potential of immuno-
histochemical method in better understanding of the
carcinogenesis and in searching of prognostic factors in
lung cancer [15-17].
The importance of galectin-3 expression remains dis-
putable. It seems to be interesting that galectin-3 expres-
sion could play different roles in another carcinomas.
The expression of galectin-3 is associated with tumor
invasion and metastatic potential in head, neck, thyroid,
gastric and colon cancers. In contrast, for some tumours
such as breast, ovarian and prostate cancer the expres-
sion of galectin-3 is inversely correlated with metastatic
potential [5].
Szoeke and co-workers investigated the prognostic value
of growth/adhesion-regulatory lectins in stage II non-
small cell lung cancers. In examinated group of 94 patients
they showed poorer prognosis for the galectin-1 and galec-
tin-3-expressing tumor in the univariate survival examina-
tion and in the multivariate analysis for the galectin-3
positive tumours. Moreover they suggest that in tumours
expressing and binding galectin-3, the distance between
the tumour cells is of prognostic significance and an
increase in the microvessel volume fraction points to a
poorer survival rate [18].
Our study doesn’t confirm the prognostic value of
galectin-3 expression. This could be connected with
relative small and heterogenous group of patients. More-
over the reason could be related also to the staining pat-
terns. We revealed only cytoplasmatic staining and this is
the main pattern of galectin-3 expression. Nuclear and
cytoplasmatic co-expression are observed relative rare
[19], but two variants of galectin-3 are known: a phos-
phorylated and a non-phosphorylated form. Phosphoryla-
tion is a requirement for its nuclear export [20]. Hubert
et co-workers studied the intracellular distribution of
galectin-3 in mouse 3T3 fibroblasts and observed that
proliferating cells showed higher expression of galectin-3
in the nucleus than in cytoplasm, but quiescent cells pre-
dominantly expressed galectin-3 in cytoplasm [21].
We observed, that galectin-3 expression was higher in
patients with lymph node metastases (tendency in Chi
2
Yatesa test and statistical significance in Chi
2 test).
Others studies confirm that increased expression of
galectins family members, could correlate with elevated
invasiveness. It has been showed in experimental study,
that increased galectin-1 expression was associated with
high levels of invasion in lung adenocarcinoma and oral
squamous cell carcinoma lines [22]. Wu et al. demon-
strated in 37 colon cancer patients, that galectin-3
expression was significantly higher in tumors with lymph
node metastasis [23]. Liang and co-workers showed in
non small cell lung cancer, that not only galectin-3
expression in tumor tissue could be connected with
occurrence of metastasis, but also higher serum level of
galectin-3 could indicate on increased risk of occult
metastasis [24].
The correlation between cyclin D1 expression and clin-
icopathological findings as well as prognosis remains dis-
putable. Mishina and al. showed that the 5-year survival
was better in patients with cyclin D1 positive tumours
(89% vs 64%), and cyclin D1 expression tended to be a
favourable prognostic factor in univariate analysis (p =
0.08) [25].
Ayeda and al. observed in 98 patients with resected
stage I and II NSCLC, that patients with cyclin D1-posi-
tive tumors had shorter survival than those with cyclin
D1-negative tumors (5-year survival rates, 48% vs 74%;
p = 0.006) [26]. Other authors didn’t confirm the prog-
nostic value of cyclin D1 expression in resectable non
small cell lung cancer [27].
We revealed only weak tendency that cyclin D1 expres-
sion was higher in patients without lymph node involve-
ment. The correlations between cyclin D1 expression and
clinicopathological findings remain disputable. Some
authors indicate, that cyclin D1 had significantly higher
positive results in patients with poorly differentiated car-
cinoma, in presence of vascular invasion and visceral
pleural invasion [26].
We revealed higher cyclin D1 expression in galectin-3
negative tumors (96.55% vs 61.11%, p = 0,0061) and
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expression (R Spearman -0.458, p = 0.0011). These
results were surprising for us, because some studies
indicate on positive correlations between these both
examinated markers in selected carcinoma types. Fer-
razzo and al. demonstrated in adenoid cystic carcinoma
of salivary glands, that cyclin D1 expression was corre-
lated with cytoplasmatic and nuclear galectin-3 expres-
sion, what could suggests that galectin-3 may play a role
in cellular activation through cyclin D1 activation, but
these authors observed in adenoid cystic carcinomas
predominately nuclear galectin-3 expression [28]. Acika-
lin et al. showed correlation between galectin-3 and
cyclin D1 expression in undifferentiated nasopharyngeal
carcinoma [29].
However the number of studies, which evaluated corre-
lations between galectin-3 and cyclin D1 expression is lim-
ited and we didn’t find any studies performed in lung
cancer tissue. Experimental studies in human breast
epithelial cells indicate that galectin-3 could down-regulate
the cyclin E and cyclin A expression [30]. The same
authors suggested that galectin-3 up-regulated cyclin D1
expression, but they observed also that galectin-3 up-regu-
lation of cyclin D1 expression enhanced in suspension cul-
tures. From the other hand it is known that cell adhesion
is required for the induction and translation of cyclin D1
mRNA, moreover in cyclin D1 expression play role differ-
ent factors [31]. That is why experimental results on cul-
tures could differ from clinical studies on tumor tissue.
Moreover as mentioned before galectin-3 expression could
play different roles in different carcinomas types [5].
We revealed also differences in correlations between
galectin-3 and cyclin D1 expression in two main histo-
pathological types of NSCLC. In squamous cell lung can-
cer we didn’t observed correlations between these both
examinated markers, and in adenocarcinoma the negative
correlation was very strong. We didn’tf i n da n ys i m i l a r
works comparing correlations between galectin-3 and
cyclin D1 expression, but the results were not so surpris-
ing for us. The differences between these both histopatho-
logical types are well known, beginning from changes in
incidence, through the differences in molecular biology
and ending in various therapeutic strategies [32].
Conclusions
We didn’t reveal any important correlations between
clinicopathological findings and galectin-3 and cyclin D1
expression and in non small cell lung cancer. We didn’t
observed also prognostic value of cyclin D1 or galectin-3
expression. But we showed higher cyclin D1 expression
in galectin-3 negative tumor tissues. We revealed also dif-
ferences in correlations between galectin-3 and cyclin D1
expression in two main histopathological types of
NSCLC.
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